PRVL Insider Trading Activity and SEC Form 4 Filings
PRVL insider trading summary
No open-market insider purchases or sales of Prevail Therapeutics Inc. (PRVL) have been reported on SEC Form 4 in the past 12 months.
Latest PRVL insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Jan 22, 2021 | Tyto Acquisition Corp | 10% Owner | Buy | $771.4M (34,284,789 @ $22.50) |
| Jan 22, 2021 | ELI LILLY & Co | 10% Owner | Buy | $771.4M (34,284,789 @ $22.50) |
| Jun 24, 2019 | Orbimed Advisors LLC | Director | Buy | $15.0M (882,352 @ $17.00) |
| Jun 24, 2019 | OrbiMed Capital GP VI LLC | Director | Buy | $15.0M (882,352 @ $17.00) |
| Jun 24, 2019 | Carl L Gordon | Director | Buy | $15.0M (882,352 @ $17.00) |
| Jun 24, 2019 | Peter A. Thompson | Director | Buy | $15.0M (882,352 @ $17.00) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.